Published in Emerg Infect Dis on January 01, 2012
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis (2015) 4.07
Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis (2014) 1.86
Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med (2014) 1.45
Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob Agents Chemother (2012) 1.13
Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs (2014) 1.10
Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. Antimicrob Agents Chemother (2013) 1.09
Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin. Antimicrob Agents Chemother (2013) 1.05
Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria. J Clin Microbiol (2014) 1.05
Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy? Eur J Clin Microbiol Infect Dis (2014) 1.02
Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med (2014) 0.99
Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob Agents Chemother (2012) 0.91
Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria. J Clin Microbiol (2013) 0.91
Identification and Characterization of a Rare Fungus, Quambalaria cyanescens, Isolated from the Peritoneal Fluid of a Patient after Nocturnal Intermittent Peritoneal Dialysis. PLoS One (2015) 0.88
Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment. Antimicrob Agents Chemother (2014) 0.87
Echinocandin resistance in Candida spp. isolated from liver transplant recipients. Antimicrob Agents Chemother (2016) 0.87
Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei. Antimicrob Agents Chemother (2014) 0.86
Chromosome 5 monosomy of Candida albicans controls susceptibility to various toxic agents, including major antifungals. Antimicrob Agents Chemother (2013) 0.86
Management of invasive candidiasis in nonneutropenic ICU patients. Ther Adv Infect Dis (2014) 0.85
Set of classical PCRs for detection of mutations in Candida glabrata FKS genes linked with echinocandin resistance. J Clin Microbiol (2014) 0.84
Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci (2015) 0.84
SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGY. Rev Inst Med Trop Sao Paulo (2015) 0.83
Multicenter Comparison of the Etest and EUCAST Methods for Antifungal Susceptibility Testing of Candida Isolates to Micafungin. Antimicrob Agents Chemother (2016) 0.82
Fluconazole and Echinocandin Resistance of Candida glabrata Correlates Better with Antifungal Drug Exposure Rather than with MSH2 Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance. Front Microbiol (2016) 0.78
SB-224289 Antagonizes the Antifungal Mechanism of the Marine Depsipeptide Papuamide A. PLoS One (2016) 0.78
Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC. J Clin Microbiol (2014) 0.78
Initial antifungal strategy does not correlate with mortality in patients with candidemia. Eur J Clin Microbiol Infect Dis (2015) 0.77
Quick Detection of FKS1 Mutations Responsible for Clinical Echinocandin Resistance in Candida albicans. J Clin Microbiol (2015) 0.76
Recurrent episodes of Candidemia due to Candida glabrata, Candida tropicalis and Candida albicans with acquired echinocandin resistance. Med Mycol Case Rep (2016) 0.75
Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of FKS Genes and Cell Wall Remodeling. Antimicrob Agents Chemother (2017) 0.75
Rare case of disseminated fusariosis in a young patient with graft vs. host disease following an allogeneic transplant. Exp Ther Med (2016) 0.75
Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility. Antimicrob Agents Chemother (2015) 0.75
Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patients. F1000Prime Rep (2015) 0.75
Candida and other yeasts of clinical importance in Aseer region, southern Saudi Arabia. Presentation of isolates from the routine laboratory setting. Saudi Med J (2014) 0.75
Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida spp. Antimicrob Agents Chemother (2017) 0.75
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Resistance to echinocandin-class antifungal drugs. Drug Resist Updat (2007) 4.63
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect (2008) 3.75
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat (2011) 3.40
Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother (2006) 3.19
Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother (2007) 2.74
Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother (2008) 2.54
Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol (2010) 2.47
Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother (2010) 2.02
Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int J Antimicrob Agents (2009) 1.36
Microsatellite marker analysis as a typing system for Candida glabrata. J Clin Microbiol (2005) 1.17
Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob Agents Chemother (2011) 1.07
Comparison of microsatellite length polymorphism and multilocus sequence typing for DNA-Based typing of Candida albicans. J Clin Microbiol (2007) 1.04
Multicenter collaborative study for standardization of Candida albicans genotyping using a polymorphic microsatellite marker. J Clin Microbiol (2010) 0.90
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 17.04
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS (2005) 5.51
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med (2004) 4.47
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis (2009) 4.09
Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med (2008) 3.85
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med (2011) 3.63
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis (2010) 3.07
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med (2009) 3.07
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med (2007) 2.85
Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother (2007) 2.74
Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med (2012) 2.55
Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother (2008) 2.54
Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BMC Genomics (2008) 2.51
Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother (2010) 2.38
Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis (2009) 2.33
Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr (2007) 2.32
Cryptococcal cell morphology affects host cell interactions and pathogenicity. PLoS Pathog (2010) 2.28
Aspergillus PCR: one step closer to standardization. J Clin Microbiol (2010) 2.23
Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis (2002) 2.20
Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS (2006) 2.19
Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun (2008) 2.15
Comparison of two DNA targets for the diagnosis of Toxoplasmosis by real-time PCR using fluorescence resonance energy transfer hybridization probes. BMC Infect Dis (2003) 2.12
Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS (2004) 2.11
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood (2006) 2.06
Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother (2010) 2.02
Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation. Clin Infect Dis (2004) 1.98
Molecular identification of zygomycetes from culture and experimentally infected tissues. J Clin Microbiol (2006) 1.96
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica (2012) 1.80
Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol (2005) 1.80
Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis (2007) 1.78
Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol (2011) 1.76
Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol (2002) 1.76
Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis (2003) 1.74
Idiopathic CD4+ T-cell lymphocytopenia is associated with impaired membrane expression of the chemokine receptor CXCR4. Blood (2009) 1.74
Long-term outcome of children with congenital toxoplasmosis. Am J Obstet Gynecol (2010) 1.66
Literature review and case histories of Histoplasma capsulatum var. duboisii infections in HIV-infected patients. Emerg Infect Dis (2007) 1.63
Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis (2009) 1.62
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis (2009) 1.60
Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii). J Clin Microbiol (2008) 1.57
β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis (2011) 1.56
Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res (2006) 1.54
Bacteremia in patients receiving TNF-alpha antagonists--a prospective multicenter study. J Infect (2013) 1.52
Routine identification of medical fungi by the new Vitek MS matrix-assisted laser desorption ionization-time of flight system with a new time-effective strategy. J Clin Microbiol (2012) 1.52
Cryptococcus neoformans Galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus Galactomannan. J Clin Microbiol (2005) 1.50
Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis. J Clin Microbiol (2002) 1.50
Cryptosporidiosis in paediatric renal transplantation. Pediatr Nephrol (2009) 1.50
Human listeriosis caused by Listeria ivanovii. Emerg Infect Dis (2010) 1.46
Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med (2014) 1.45
Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol (2011) 1.45
Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans. Mol Microbiol (2002) 1.45
Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis (2012) 1.45
Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis (2008) 1.44
Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One (2008) 1.43
Healthcare-associated mucormycosis. Clin Infect Dis (2012) 1.42
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Schistosomiasis haematobium, Corsica, France. Emerg Infect Dis (2014) 1.39
Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis. J Clin Microbiol (2005) 1.38
Molecular and phenotypic evaluation of Lichtheimia corymbifera (formerly Absidia corymbifera) complex isolates associated with human mucormycosis: rehabilitation of L. ramosa. J Clin Microbiol (2009) 1.36
International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother (2010) 1.35
Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.34
Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother (2009) 1.34
Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore) (2012) 1.31
AIDS patient death caused by novel Cryptococcus neoformans x C. gattii hybrid. Emerg Infect Dis (2008) 1.31
Cryptococcus neoformans capsule structure evolution in vitro and during murine infection. Infect Immun (2004) 1.31
Detection of caspofungin resistance in Candida spp. by Etest. J Clin Microbiol (2008) 1.29
Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am (2010) 1.29
Molecular identification of black-grain mycetoma agents. J Clin Microbiol (2006) 1.28
Complete glycosylphosphatidylinositol anchors are required in Candida albicans for full morphogenesis, virulence and resistance to macrophages. Mol Microbiol (2002) 1.28
Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Infect Immun (2003) 1.27
High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother (2011) 1.27
Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis (2014) 1.25